ERA 2025 - Dr Ruben Nogueiras (University of Santiago de Compostela, Santiago, ES) joins us to discuss upcoming treatments that will soon be approved for the treatment of obesity, including dual agonists that will also target type two diabetes. As well as exploring the evolution of our understanding and classification of obesity, Dr Nogueiras shares his view of obesity a multifactorial disease that should to be managed by a network of experts.

Interview Questions:
1. What are the most significant advances in obesity management as of 2025?
2. How has the medical definition of obesity evolved in recent years, and what does it mean to now classify it as a chronic disease?
3. What role do nephrologists play in multidisciplinary obesity care, and how can collaboration be improved?
4. Are newer obesity drugs safe and effective for patients with moderate to severe CKD?
5. Are there any promising emerging therapies that you believe will become mainstream?

Recorded on-site at ERA in Vienna, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David-Ben Harosh, Tom Green

Support: This is an independent interview produced by Radcliffe CVRM.